In the context of cancer treatment, such a device could efficiently detect specific genetic mutations that are known to respond well to particular therapies (e.g., KRAS, HER2, EGFR, etc.), resulting in improved drug efficacy and an optimized-for-the-individual approach to treatment [64]. This evidence concerns the gene ERBB2 and cancer.